By delivering retatrutide preferentially to the brain, researchers might achieve appetite suppression and metabolic regulation through central mechanisms while minimizing peripheral GI receptor activation
This content is for informational purposes only and should not be viewed as a substitute for medical advice
By adding glucagon receptor activation to GLP-1 and GIP agonism, retatrutide adds a third distinct mechanism to the weight loss equation: not just reduced calorie intake (GLP-1, GIP) but increased calorie burning (glucagon)
When protein intake is insufficient, the body may break down muscle tissue for energy, which can result in: Weakened muscles and reduced strength A slower metabolism, making calorie burning less efficient An increased risk of regaining weight after stopping the medication Additionally, research suggests that GLP-1 therapy decreases muscle protein synthesis, meaning the body has a harder time rebuilding lost muscle
Following completion of neoadjuvant systemic therapy, a standard SLNB is performed along with removal of the clipped node
The pattern matters for litigation
